TDC
LGND icon

Thompson Davis & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Thompson Davis & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-248
Closed -$21K – 897
2017
Q3 		$21K Buy
+248
New +$19.6K 0.04% 466

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Thompson Davis & Co's LGND Position: Q4 2017 in Review

Thompson Davis & Co sold out of Ligand Pharmaceuticals (LGND) in Q4 2017, closing a stake of 248 shares — an estimated $21K sold.

Thompson Davis & Co first reported a position in LGND in Q3 2017 and held it in 1 quarter. The position peaked at $21K in Q3 2017. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

  • Thompson Davis & Co reported no remaining Ligand Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 248 Ligand Pharmaceuticals shares in Q4 2017, an estimated $21K.
  • Thompson Davis & Co first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Ligand Pharmaceuticals position peaked at $21K in Q3 2017.
  • 298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.